With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.31886-58-5,(R)-(+)-N,N-Dimethyl-1-ferrocenylethylamine,as a common compound, the synthetic route is as follows.,31886-58-5
15.4 ml of a cyclohexane solution of s-butyllithium (1.3 M, 22 mmol) are added to a solution of 5.14 g (20 mmol) of (R)-N, N-dimethyl-1 -ferrocenylethylamine [(R)-ugi- amine] in 30 ml of t-butyl methyl ether (TBME) at -78C over a period of 10 minutes. The mixture is then heated to room temperature while stirring and maintained at this temperature for 1.5 hours. It is then cooled back down to -78 0C and 2.71 ml(20 mmol) of dichlorophenylphosphine are added over a period of 10 minutes. After stirring at -78C for 10 minutes, the mixture is allowed to warm slowly to room temperature and is stirred at this temperature for 1.5 hours.
As the paragraph descriping shows that 31886-58-5 is playing an increasingly important role.
Reference£º
Patent; SOLVIAS AG; WO2008/55942; (2008); A1;,
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis